Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?

ABSTRACT:

Importance

Combination therapies of anti-PD-1 and anti-angiogenesis regimens are emerging rapidly and exhibit more promising anti-tumor efficacy for advanced hepatocellular carcinoma (HCC), and consistently it is the hotspot in clinical studies.

Objective

To elaborate several issues which are warranted further consideration as more regimens are being investigated in combination therapies.

Evidence review

We searched PubMed, MEDLINE, Cochrane Library and Google Scholar by 2021 February for publications on combination therapies for HCC.

Findings

Several clinical issues are worth reconsidering, such as the evaluation on appropriate primary endpoints in phase III clinical trials as for different practical problems, the translation of surrogate endpoint objective re

SUBMITTER: Zhang T 

PROVIDER: S-EPMC8050575 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature